A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used for managing type 2 diabetes and obesity. As their clinical applications expand, interest in their safety and adverse effects has grown. This study provides a comprehensive bi…
BACKGROUND: GLP- 1 RA have been reported to decrease cancer incidence, but less is known about their potential in patients with active cancer. Preclinical studies have demonstrated that GLP-1 RA inhibit progression of solid tumor malignancies via dow…
Metabolic dysfunction associated fatty liver disease (MAFLD) is a rapidly growing global health burden characterized by hepatic lipid accumulation, insulin resistance, oxidative stress, and inflammation. Phyllanthus niruri (PHYLN) is rich in polyphen…
BACKGROUND: A number of novel antidiabetic drugs have been developed. These drugs include sodium-glucose cotransporter 2 inhibitors (SGLT-2is), glucagon-like peptide-1 receptor agonists (GLP-1RAs), and dipeptidyl peptidase-4 inhibitors (DPP-4is). How…
Glucocorticosteroids (GCs) are commonly used in the treatment of autoimmune, inflammatory and neoplastic diseases. Although clinically effective, they are associated with significant metabolic side effects, including increased insulin resistance, imp…
Polycystic ovary syndrome (PCOS) is a common, heterogeneous condition that is tightly linked to obesity, visceral adiposity and insulin resistance. Lifestyle intervention and off-label use of metformin provide only modest and unsustained weight loss,…
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1s) have been associated with reduced atrial fibrillation (AF) incidence. Although weight loss is a known benefit of GLP-1 therapy and an established AF risk modifier, it remains unclear whet…
BACKGROUND: Obesity is a heterogeneous chronic disease in which eating behavior phenotypes may influence treatment response. Yet, anti-obesity medication (AOM) selection is still largely guided by anthropometric and metabolic parameters, with limited…
AIMS: Young adults (aged ≤ 40 years) are underrepresented in clinical trials that investigate interventions for those living with Type 2 diabetes (T2D). This study evaluated the efficacy of semaglutide treatment in young adults with T2D by examining…
AIMS: Treatment options for adolescents with obesity are limited, and some may benefit from lower maintenance doses of semaglutide. This study used model-informed drug development (MIDD) to evaluate whether a 1.7-mg maintenance dose provides comparab…
BACKGROUND: Diabetic nephropathy (DN) is a major microvascular complication of type 2 diabetes and a leading cause of end-stage renal disease. Both canagliflozin and semaglutide are recommended for diabetic nephropathy, yet direct evidence comparing…
PURPOSE: The Inflation Reduction Act (IRA) introduced significant reforms to Medicare Part D in 2025, aiming to reduce medication costs for beneficiaries by eliminating the coverage gap ("donut hole") with a $2,000 annual out-of-pocket cap. However,…
INTRODUCTION: Once-weekly semaglutide has proven to be a safe and effective treatment for type 2 diabetes; however, clinical trial data on Asian populations are limited, warranting real-world data (RWD). In this study we assessed the effectiveness an…
Recent studies have reported a possible association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and non-arteritic anterior ischemic optic neuropathy (NAION). The North American Neuro-Ophthalmology Society and the American Academy of…
BACKGROUND: Semaglutide, a glucagon-like peptide-1(GLP-1) receptor agonist, is an effective treatment for type 2 diabetes and weight loss. However, its high cost poses a significant barrier to access for those who need it more. This study investigate…
BACKGROUND: Glucagon-like peptide-1 receptor agonists, originally developed for managing type 2 diabetes, have gained attention for their weight-reducing and broader biological effects. Among these, their influence on human mesenchymal stem cells rem…
BACKGROUND: Despite the clinical efficacy of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for weight loss, real-world persistence remains substantially lower than seen in clinical trials. Since 2021, GLP-1RA shortages and changes in product a…